BSE · 544694
Accretion Nutraveda Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹34 Cr with net profit ₹5 Cr — a 15.03% net margin, versus 15.62% the period before.
Shareholding
As of 2026-09-30
- Promoter73.48%
- Public20.33%
- FII1.08%
- DII5.11%
380 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.09× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 51 by market cap · medians across 44 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,73,067 Cr | 77.57 | 9.46 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,927 Cr | 40.95 | 4.53 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹42,249 Cr | 37.23 | 9.4 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,669 Cr | 85.6 | 19.2 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹17,618 Cr | 61.95 | 6.8 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,284 Cr | 25.98 | 5.12 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,333 Cr | 23.35 | 3.7 | 17.07% | 21.36% |
| Marksans Pharma Limited | ₹13,443 Cr | 26.02 | 4.45 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,596 Cr | 47.92 | 5.5 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,736 Cr | 45.39 | 6.15 | 12.36% | 18.59% |
| Accretion Nutraveda Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAccretion Nutraveda Limited is currently under ESM Stage 1 surveillance. The company reported annual revenue of Rs 16.06 Cr for March 2025. Promoter holding stands at 73.48% as of June 2026, with no shares pledged.
Positives
- +Promoter holding is high at 73.48% as of June 2026, indicating significant insider confidence.
- +Debt-to-equity ratio is 0.94, which is below 1.
- +The company has no pledged promoter shares as of June 2026.
Negatives
- −The company is under ESM Stage 1 surveillance, which may indicate higher risk.
- −Revenue growth information for specific periods is not available in the provided data.
- −Profit margin details are not provided for any period.
- −Missing key financial metrics such as market capitalization, P/E ratio, and book value.
- −Historical shareholding data for 'others' shows fluctuations, from 3.56% in June 2026 to 0% in September 2025.
Financial Performance
Accretion Nutraveda Limited's annual revenue increased to Rs 16.06 Cr in March 2025 from Rs 5.20 Cr in March 2024. Net profit also rose to Rs 2.61 Cr in March 2025 compared to Rs 0.82 Cr in March 2024. Earnings per share (EPS) were Rs 71.91 in March 2025, up from Rs 22.83 in March 2024.
Balance Sheet
The company has a debt-to-equity ratio of 0.94. No other specific balance sheet figures such as market capitalization, book value, or return ratios like ROE or ROCE are available in the provided data.
Ownership & Pledges
The total number of shareholders is 396.
Regulatory & Surveillance
Accretion Nutraveda Limited is currently classified under ESM Stage 1 surveillance. This indicates closer monitoring by regulatory bodies due to specific criteria met under the Enhanced Surveillance Measure framework.
Data as of — price: 2026-10-27 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Accretion Nutraveda Limitedshare price & fundamentals